| 1 |
Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence[J]. Diabetes Obes Metab, 2014, 16 (2): 111-117.
|
| 2 |
Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035[J]. Diabetes Res Clin Pract, 2014, 103 (2): 137-149.
|
| 3 |
陈忻，翟所迪. GLP-1类似物与DPP-4抑制剂的对比综述[J]. 药品评价，2013，(11):20-23.
|
| 4 |
Bayliss WM, Starling EH. The mechanism of pancreatic secretion[J]. J Physiol, 1902, 28 (5): 325-353.
|
| 5 |
Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment[J]. Pharmacol Rev, 2008, 60 (4): 470-512.
|
| 6 |
Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration[J]. J Clin Endocrinol Metab, 1964, 24: 1076-1082.
|
| 7 |
Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects[J]. J Clin Invest, 1967, 46 (12): 1954-1962.
|
| 8 |
Ebert R, Unger H, Creutzfeldt W. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption[J]. Diabetologia, 1983, 24 (6): 449-454.
|
| 9 |
Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides[J]. Nature, 1983, 302 (5910): 716-718.
|
| 10 |
Lund PK, Goodman RH, Dee PC, et al. Pancreatic pre-proglucagon cDNA contains two glucagon-related coding sequences arranged in tandem[J]. Proc Natl Acad Sci U S A, 1982, 79 (2): 345-349.
|
| 11 |
Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets[J]. Diabetologia, 1985, 28 (9): 704-707.
|
| 12 |
Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes[J]. Diabetologia, 1986, 29 (1): 46-52.
|
| 13 |
Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man[J]. Lancet, 1987, 2 (8571): 1300-1304.
|
| 14 |
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet, 2006, 368 (9548): 1696-1705.
|
| 15 |
Toft-Nielson M, Madsbad S, Holst JJ. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones[J]. Diabetes, 1996, 45 (5): 552-556.
|
| 16 |
Wu T, Rayner CK, Jones K, et al. Dietary effects on incretin hormone secretion[J]. Vitam Horm, 2010 (84): 81-110.
|
| 17 |
Holst JJ. The physiology of glucagon-like peptide 1[J]. Physiol Rev, 2007, 87 (4): 1409-1439.
|
| 18 |
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP[J]. Gastroenterology, 2007, 132 (6): 2131-2157.
|
| 19 |
Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology[J]. Diabetes Metab Res Rev, 2005, 21 (2): 91-117.
|
| 20 |
Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse[J]. Endocrinology, 1994, 134 (5): 2156-2164.
|
| 21 |
Li Y, Cao X, Li LX, et al. Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1[J]. Diabetes, 2005, 54 (2): 482-491.
|
| 22 |
Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis[J]. J Biol Chem, 2003, 278 (1): 471-478.
|
| 23 |
Marathe CS, Rayner CK, Jones KL, et al. Glucagon-like peptides 1 and 2 in health and disease: a review[J]. Peptides, 2013 (44): 75-86.
|
| 24 |
Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes[J]. Diabetes, 2003, 52 (1): 102-110.
|
| 25 |
Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients[J]. Diabetes Care, 1996, 19 (6): 580-586.
|
| 26 |
Franklin I, Gromada J, Gjinovci A, et al. Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release[J]. Diabetes, 2005, 54 (6): 1808-1815.
|
| 27 |
Schick RR, Zimmermann JP, vorm Walde T, et al. Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats[J]. Am J Physiol Regul Integr Comp Physiol, 2003, 284 (6): R1427-1435.
|
| 28 |
Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man[J]. Dig Dis Sci, 1993, 38 (4): 665-673.
|
| 29 |
Wettergren A, Wojdemann M, Meisner S, et al. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation[J]. Gut, 1997, 40 (5): 597-601.
|
| 30 |
D'Alessio D, Vahl T, Prigeon R. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism[J]. Horm Metab Res, 2004, 36 (11-12): 837-841.
|
| 31 |
Valverde I, Morales M, Clemente F, et al. Glucagon-like peptide 1: a potent glycogenic hormone[J]. FEBS Lett, 1994, 349 (2): 313-316.
|
| 32 |
Ikezawa Y, Yamatani K, Ohnuma H, et al. Glucagon-like peptide-1 inhibits glucagon-induced glycogenolysis in perivenous hepatocytes specifically[J]. Regul Pept, 2003, 111 (1-3): 207-210.
|
| 33 |
彤丹，闫玮. 2型糖尿病患者颈动脉内-中膜厚度与血管内皮功能的超声评价及其相关性研究[J/CD]. 中华危重症医学杂志（电子版），2014，7(2):123-125.
|
| 34 |
王丽红，张琴，姜久昆. 通心络对2型糖尿病患者血管内皮功能和炎症反应的干预研究[J/CD]. 中华危重症医学杂志（电子版），2015，8(3):165-168.
|
| 35 |
Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists[J]. Am J Cardiol, 2011, 108 (3 Suppl): 33B-41B.
|
| 36 |
Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice[J]. Diabetes, 2009, 58 (4): 975-983.
|
| 37 |
Cantini G, Mannucci E, Luconi M. Perspectives in GLP-1 research: new targets, new receptors[J]. Trends Endocrinol Metab, 2016, 27 (6): 427-438.
|
| 38 |
Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways[J]. Circulation, 2008, 117 (18): 2340-2350.
|
| 39 |
Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action[J]. Cell Metab, 2013, 17 (6): 819-837.
|
| 40 |
Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron[J]. J Neurosci Res, 2003, 72 (5): 603-612.
|
| 41 |
During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection[J]. Nat Med, 2003, 9 (9): 1173-1179.
|
| 42 |
Ma T, Du X, Pick JE, et al. Glucagon-like peptide-1 cleavage product GLP-1 (9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice[J]. J Neurosci, 2012, 32 (40): 13701-13708.
|
| 43 |
Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis[J]. BMC Neurosci, 2012 (13): 33.
|
| 44 |
Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides[J]. Prog Neurobiol, 2010, 92 (3): 442-462.
|
| 45 |
Gao Y, Ottaway N, Schriever SC, et al. Hormones and diet, but not body weight, control hypothalamic microglial activity[J]. Glia, 2014, 62 (1): 17-25.
|
| 46 |
Mossello E, Ballini E, Boncinelli M, et al. Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities[J]. Exp Diabetes Res, 2011: 281674.
|
| 47 |
Teramoto S, Miyamoto N, Yatomi K, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia[J]. J Cereb Blood Flow Metab, 2011, 31 (8): 1696-1705.
|
| 48 |
Challa TD, Beaton N, Arnold M, et al. Regulation of adipocyte formation by GLP-1/GLP-1R signaling[J]. J Biol Chem, 2012, 287 (9): 6421-6430.
|
| 49 |
Yang J, Ren J, Song J, et al. Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes[J]. Int J Mol Med, 2013, 31 (6): 1429-1435.
|
| 50 |
Kim Chung le T, Hosaka T, Yoshida M, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression[J]. Biochem Biophys Res Commun, 2009, 390 (3): 613-618.
|
| 51 |
Yamada C, Yamada Y, Tsukiyama K, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption[J]. Endocrinology, 2008, 149 (2): 574-579.
|
| 52 |
Nuche-Berenguer B, Lozano D, Gutierrez-Rojas I, et al. GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia[J]. J Endocrinol, 2011, 209 (2): 203-210.
|
| 53 |
Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, et al. Receptors and effects of gut hormones in three osteoblastic cell lines[J]. BMC Physiol, 2011 (11): 12.
|
| 54 |
Nuche-Berenguer B, Moreno P, Portal-Nunez S, et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states[J]. Regul Pept, 2010, 159 (1-3): 61-66.
|
| 55 |
Meier C, Schwartz AV, Egger A, et al. Effects of diabetes drugs on the skeleton[J]. Bone, 2016 (82): 93-100.
|
| 56 |
Nuche-Berenguer B, Moreno P, Esbrit P, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states[J]. Calcif Tissue Int, 2009, 84 (6): 453-461.
|
| 57 |
Meng J, Ma X, Wang N, et al. Activation of GLP-1 re-ceptor promotes bone marrow stromal cell osteogenic differentiation through beta-catenin[J]. Stem Cell Reports, 2016, 6 (4): 633.
|
| 58 |
Monami M, Dicembrini I, Antenore A, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials[J]. Diabetes Care, 2011, 34 (11): 2474-2476.
|
| 59 |
Lee YS, Park MS, Choung JS, et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes[J]. Diabetologia, 2012, 55 (9): 2456-2468.
|
| 60 |
Iwai T, Ito S, Tanimitsu K, et al. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes[J]. Neurosci Res, 2006, 55 (4): 352-360.
|
| 61 |
Wang XC, Gusdon AM, Liu H, et al. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation[J]. World J Gastroenterol, 2014, 20 (40): 14821-14830.
|
| 62 |
Bond A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus[J]. Proc (Bayl Univ Med Cent), 2006, 19 (3): 281-284.
|
| 63 |
Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent[J]. Toxicon, 2012, 59 (4): 464-471.
|
| 64 |
Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea[J]. Diabetes Care, 2005, 28 (5): 1083-1091.
|
| 65 |
Lim SM, Eom HN, Jiang HH, et al. Evaluation of PEGylated exendin-4 released from poly (lactic-coglycolic acid) microspheres for antidiabetic therapy[J]. J Pharm Sci, 2015, 104 (1): 72-80.
|
| 66 |
Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men[J]. Diabetologia, 2002, 45 (2): 195-202.
|
| 67 |
Christensen M, Knop FK, Vilsboll T, et al. Lixisenatide for type 2 diabetes mellitus[J]. Expert Opin Investig Drugs, 2011, 20 (4): 549-557.
|
| 68 |
Bush MA, Matthews JE, De Boever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects[J]. Diabetes Obes Metab, 2009, 11 (5): 498-505.
|
| 69 |
Woodward HN, Anderson SL. Once-weekly albiglutide in the management of type 2 diabetes: patient considerations[J]. Patient Prefer Adherence, 2014 (8):789-803.
|
| 70 |
Bao W, Aravindhan K, Alsaid H, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency[J]. PLoS One, 2011, 6 (8): e23570.
|
| 71 |
Jimenez-Solem E, Rasmussen MH, Christensen M, et al. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes[J]. Curr Opin Mol Ther, 2010, 12 (6): 790-797.
|
| 72 |
Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis[J]. Diabetes Obes Metab, 2014, 16 (1): 30-37.
|
| 73 |
Vella A, Bock G, Giesler PD, et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study[J]. Clin Endocrinol (Oxf), 2008, 69 (5): 737-744.
|
| 74 |
Tan X, Hu J. Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes[J]. Expert Opin Pharmacother, 2016, 17 (9): 1285-1293.
|
| 75 |
Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label Liraglutide in patients with type 2 diabetes[J]. Diabetes Care, 2016, 39 (2): 231-241.
|
| 76 |
Eldor R, Kidron M, Greenberg-Shushlav Y, et al. Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models[J]. J Diabetes Sci Technol, 2010, 4 (6): 1516-1523.
|